Company and Case Information

Home

Index of Filings

News and Press Releases

Filings

Decisions

Settlements

Litigation Activity Indices

Top Ten List

Annual/Quarterly Updates

Clearinghouse Research

Articles & Papers

Search

Related Sites

About Us

Local Rules

Sponsors


Register


_______________
Copyright (c) 2001
Stanford Law School


Cellcyte Genetics Corporation
Summary: The class-action lawsuit against CellCyte for alleges violations of securities laws. According to the complaint CellCyte executives and business partners misled investors by publishing false information about the history and experience of the company’s chief executive officer.

The lawsuit alleges that company shares were traded at artificially inflated prices due to the company’s activities.

The company’s chief executive officer’s education and professional credentials were called into question after published news reports called out alleged discrepancies relating to his finance degree from the University of Washington, a CPA designation, ties to the Washington Society of Certified Public Accountants and a strong track record within the pharmaceutical industry. Soon after these reports company stock plummeted 55 percent.

INDUSTRY CLASSIFICATION:
SIC Code: 2834
Sector: Healthcare
Industry: Biotechnology & Drugs


COMPANY/ISSUER NAME: Cellcyte Genetics Corporation
COMPANY/ISSUER TICKER: CCYG
COMPANY WEBSITE: http://www.cellcyte.com

FIRST IDENTIFIED COMPLAINT IN THE DATABASE
Lance Armbruster, et al. v. Cellcyte Genetics Corporation, et al.
 COURT: W.D. Washington  DOCKET NUMBER: 08-CV-00047
 JUDGE NAME: Hon. Robert S. Lasnik
 DATE FILED: 01/14/2008  SOURCE: Notice of Filing
 CLASS PERIOD START: 04/06/2007  CLASS PERIOD END: 01/09/2008
 TYPE OF COMPLAINT: Unamended/Unconsolidated
 PLAINTIFF FIRMS IN THIS OR SIMILAR CASE:
  • Cohen, Milstein, Hausfeld & Toll, P.L.L.C. (Washington, DC)
      1100 New York Avenue, N.W., Suite 500, West Tower, Washington, DC, 20005
       (voice) 202.408.4600, (fax) 202.408.4699, lawinfo@cmht.com
  • Hagens Berman Sobol Shapiro LLP
      1301 Fifth Avenue, Suite 2900, Seattle, WA, 98101
       (voice) 206-623-7292, (fax) 206-623-0594, info@hagens-berman.com
  • Keller Rohrback LLP
      1201 Third Avenue, Suite 3200, Seattle, WA, 98101-3052 Av
       (voice) 800.776.6044, (fax) 206.623.3384, investor@kellerrohrback.com
    _____________________________________________
     TOTAL NUMBER OF PLAINTIFF FIRMS:  3

  •  DOCUMENTS FOR THE FIRST IDENTIFIED COMPLAINT
    Class Action Complaint for Violations of the Federal Securities Laws - Jury Trial Demanded
    Type: Complaint Date on the document: 01/14/2008

     OTHER DOCUMENTS
    Class Action Complaint for Violation of the Federal Securities Laws - Demand for Jury Trial
    Case Name and/or Number: Dominic J. Tolerico, et al. v. Cellcyte Genetics Corporation, et al.
    Type: Complaint Date on the document: 02/01/2008
    Class Action Complaint for Violations of the Federal Securities Laws - Jury Trial Demanded
    Case Name and/or Number: Joe M. Pruitt, et al. v. Cellcyte Genetics Corporation, et al.
    Type: Complaint Date on the document: 02/01/2008

    WARNING AND DISCLAIMER OF LIABILITY:
    The information included on this Web site, whether provided by personnel employed by Stanford Law School or by third parties, is provided for research and teaching purposes only. Neither Stanford University, Stanford Law School, nor any of their employees, agents, contractors, or affiliates warrant the accuracy or completeness of the information or analyses displayed herein, and we caution all readers that inclusion of any information on this site does not constitute an endorsement of the truthfulness or accuracy of that information. In particular, this Web site contains complaints and other documents filed in federal and state courts, which make allegations that may or may not be accurate. No reader should, on the basis of information contained in or referenced by this Web site, assume that any of these allegations are truthful.
    Go to Search  page | Go to Case Index  page | Back to Top